Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. (MTNB) Financial Performance & Income Statement Overview
Analyze Matinas BioPharma Holdings, Inc. (MTNB) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Matinas BioPharma Holdings, Inc. (MTNB) Income Statement & Financial Overview
Explore comprehensive income reports for Matinas BioPharma Holdings, Inc. MTNB, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $962000.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $241000.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$241000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | ||
| R&D Expenses | $85000.00 | $2.38M | $2.24M | $3.37M |
| SG&A Expenses | $1.86M | $1.66M | $2.14M | $2.47M |
| Operating Expenses | $1.95M | $3.79M | $4.38M | $5.84M |
| Total Costs & Expenses | $1.95M | $8.47M | $4.38M | $5.84M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $247000.00 | $244000.00 | $241000.00 |
| EBITDA | -$1.95M | -$3.79M | -$4.14M | -$5.60M |
| EBITDA Ratio | -$3.94 | |||
| Operating Income | -$1.95M | -$4.04M | -$4.38M | -$5.84M |
| Operating Income Ratio | -$4.20 | |||
| Other Income/Expenses (Net) | $290000.00 | -$4.47M | $106000.00 | $120000.00 |
| Income Before Tax | -$1.66M | -$8.51M | -$4.28M | -$5.72M |
| Income Before Tax Ratio | -$8.85 | |||
| Income Tax Expense | $0.00 | -$80000.00 | $0.00 | $0.00 |
| Net Income | -$1.66M | -$8.43M | -$4.28M | -$5.72M |
| Net Income Ratio | -$8.77 | |||
| EPS | -$0.33 | -$1.73 | -$0.85 | -$1.15 |
| Diluted EPS | -$0.33 | -$1.73 | -$0.85 | -$1.15 |
| Weighted Avg Shares Outstanding | $5.09M | $4.87M | $5.04M | $4.99M |
| Weighted Avg Shares Outstanding (Diluted) | $5.09M | $4.87M | $5.04M | $4.99M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$1.95M in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.95M. Net income rose to -$1.66M, keeping EPS at -$0.33. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan